South Korea Dravet Syndrome Market Size, Share, and COVID-19 Impact Analysis, By Type of Seizures (Myoclonic seizures, Atonic seizures, Partial seizures, Absence seizures, Tonic seizures, Photosensitive seizures, and Others), By Treatment Management (Seizure Medications, Ketogenic Diet, Vagus Nerve Stimulation, and Others), and South Korea Dravet Syndrome Market Insights, Industry Trend, Forecasts to 2035

South Korea Dravet Syndrome Market Insights Forecasts to 2035

• The South Korea Dravet Syndrome Market Size was Estimated at USD 13.75 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 8.72% from 2025 to 2035
• The South Korea Dravet Syndrome Market Size is Expected to Reach USD 34.5 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, the South Korea Dravet Syndrome Market Size is Anticipated to Reach USD 34.5 Million by 2035, Growing at a CAGR of 8.72% from 2025 to 2035. Growing by the creation of novel therapies like gene-based and cannabinoid treatments, greater government support for the treatment of rare diseases, and growing awareness among medical professionals.

Market Overview

The South Korea Dravet syndrome market refers to the medical ecosystem devoted to identifying, treating, and managing Dravet syndrome a severe and uncommon form of epilepsy that usually starts in infancy and is frequently caused by mutations in the SCN1A gene is referred to as the South Korean Dravet Syndrome market. Additionally, South Korea offers a special chance for the development and approval of novel drugs that specifically address Dravet syndrome due to its supportive clinical trial regulations. This cooperative approach could support the focus on patient access, guaranteeing that cutting-edge medications get to affected families as soon as possible. Further, recent patterns indicate a greater focus on support systems for families affected by Dravet syndrome. The medical community and the general public are becoming more knowledgeable about this complex illness as a result of the growing number of initiatives to increase awareness and educate people about it. Moreover, relationships between families, caregivers, and medical professionals are facilitated by the widespread use of internet platforms, creating opportunities for collective advocacy and shared experiences. The goal of this all-encompassing approach is to improve the standard of living for Dravet Syndrome patients and their families in South Korea.

Report Coverage

This research report categorizes the market for the South Korea Dravet syndrome market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea Dravet syndrome market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the South Korea Dravet syndrome market.

Driving Factors

The South Korean Dravet syndrome industry is benefiting from rising awareness and education about the condition. To educate the public and medical professionals about Dravet syndrome, its symptoms, and available treatments, non-profit organizations and medical associations in South Korea, like the Korean Society of Child Neurology, are actively holding seminars, workshops, and campaigns. The fact that misdiagnosis rates have dropped by about 30%, enabling prompt intervention and treatment, is a noteworthy result of these efforts. Since early diagnosis can significantly improve outcomes for children with Dravet syndrome, these initiatives are essential. Consequently, the market has seen a sharper demand for treatment solutions, which has led to an estimated 15% increase in market potential as more families seek professional medical advice after identifying symptoms.

Restraining Factors

The Dravet syndrome market in South Korea is constrained by high treatment costs, delayed diagnosis, low awareness, and regulatory barriers. Access to efficient treatments is hampered by misdiagnosis and inadequate specialized care. Drug development is hampered by small patient pools and the complexity of clinical trials. The stigma associated with epilepsy and insurance restrictions also hinder the uptake of novel treatments, which slows the growth of the market as a whole.

Market Segmentation

The South Korea dravet syndrome market share is classified into type of seizures and treatment management.

• The myoclonic seizures segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea dravet syndrome market is segmented by type of seizures into myoclonic seizures, atonic seizures, partial seizures, absence seizures, tonic seizures, photosensitive seizures, and others. Among these, the myoclonic seizures segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. Since myoclonic seizures, which are characterized by sudden, involuntary muscle jerks, are common in people with Dravet syndrome and frequently increase the overall seizure burden, they are especially significant.

• The seizure medications segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea dravet syndrome market is segmented by treatment management into seizure medications, ketogenic diet, vagus nerve stimulation, and others. Among these, the seizure medications segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. The market dominance of seizure medications is highlighted by the important role they play in controlling and lowering the frequency of seizures that patients experience.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea Dravet syndrome market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Takeda Pharmaceutical Co. Ltd.
• Eisai Co. Ltd.
• Biogen Inc.
• UCB SA
• Jazz Pharmaceuticals plc
• Stoke Therapeutics Inc.
• Others

Recent Developments:

• In December 2024, Stoke Therapeutics, Inc., a biotechnology company specializing in RNA-based therapies to restore protein expression, received Breakthrough Therapy Designation from the U.S. FDA for zorevunersen in the treatment of Dravet syndrome with a confirmed SCN1A gene mutation (excluding gain-of-function mutations). Zorevunersen was being developed as a potential first-in-class disease-modifying therapy for Dravet syndrome

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea Dravet Syndrome Market based on the below-mentioned segments:

South Korea Dravet Syndrome Market, By Type of Seizures

• Myoclonic seizures
• Atonic seizures
• Partial seizures
• Absence seizures
• Tonic seizures
• Photosensitive seizures
• Others

South Korea Dravet Syndrome Market, By Treatment Management

• Seizure Medications
• Ketogenic Diet
• Vagus Nerve Stimulation
• Others